Epredia - About the company
Epredia is an unfunded company based in United Kingdom, founded in 2019. It operates as a Developer of in-vitro diagnostic test for cancer. Epredia has not raised any funding yet. The company has 443 active competitors, including 143 funded and 94 that have exited. Its top competitors include companies like Illumina, Caris Life Sciences and Geneoscopy.
Company Details
Developer of an in-vitro diagnostic test for cancer. The company develops pathological instruments to enhance cancer diagnostics. The product catalog includes tissue processors, microtomes, cyclotomy, and tracking solutions.
Key Metrics
Founded Year
2019
Location
Stage
Unfunded
Ranked
37th among 443 active competitors
Employee Count
759 as on Sep 30, 2026
Investment & Acquisitions
Sign up to download Epredia's company profile
Epredia's funding and investors
Epredia has not raised any funding rounds yet.
Epredia's founders and board of directors
Founder? Claim ProfileEpredia's employee count trend
Epredia has 759 employees as of Sep 26. Here is Epredia's employee count trend over the years:
Uncover Epredia's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Epredia's Competitors and alternates
Top competitors of Epredia include Illumina, Caris Life Sciences and Geneoscopy. Here is the list of Top 10 competitors of Epredia, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Illumina 1993, San Diego (United States), Public | Developer of technologies for analysis of genetic variation and function | $28M | 71/100 | |
2nd | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 71/100 | |
3rd | Geneoscopy 2015, St. Louis (United States), Series C | Developer of non-invasive biomarker tests for colorectal cancer | $219M | 67/100 | |
4th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 66/100 | |
5th | Arbor Biotechnologies 2016, Cambridge (United States), Series C | Provider of genomic technologies and drug discovery platform | $304M | 64/100 | |
6th | Provider of gene sequencing instruments, reagents, equipment, and related products | $1B | 63/100 | ||
7th |  Deep Genomics 2014, Toronto (Canada), Series C | AI-powered platform for RNA biology to accelerate genetic therapy discovery | $238M | 62/100 | |
8th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 62/100 | |
9th | Regulus Therapeutics 2007, San Diego (United States), Acquired | Innovative medicines company reimagining medicine to improve and extend people’s lives | $35M | 62/100 | |
10th |  Eclipse Bio 2017, San Diego (United States), Series A | Developer of cell-free immunoassay | $18.9M | 61/100 | |
37th | Epredia 2019, United Kingdom, Unfunded | Developer of in-vitro diagnostic test for cancer | - | - | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Epredia's competitors? Click here to see the top ones
Epredia's Investments and acquisitions
Epredia has a total of 1 investment in Aiforia. Epredia has not made any acquisitions as of now.Reports related to Epredia
Here is the latest report on Epredia's sector:
News related to Epredia
Filter this listMedia has covered Epredia for a total of 4 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
Leeds Pathology Tech Secures Global Deal with Cancer Diagnostics LeaderTheBusinessDesk.com•Aug 21, 2026•Epredia, Leeds Teaching Hospitals NHS
•
•
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer DiagnosticsBusiness Wire•Feb 24, 2026•Mindpeak, Epredia
•
FDA clears Epredia's E1000 Dx digital pathology system for faster cancer diagnostics.Business Wire•Mar 04, 2025•Epredia
•
Epredia Receives Innovative Technology Designation from Vizient for SlideMate™ Laser Slide PrinterBusiness Wire•Nov 01, 2024•Epredia, PHC Holdings
•
Epredia, NovaScan Devise U.S. Distribution Agreement for MarginScan DeviceMedical Product Outsourcing•Jun 11, 2024•NovaScan, Epredia
•
•
•
Epredia Announces the U.S. Launch of SlideMate™ Laser, Providing State-of-the-Art Precision Slide Printing for Pathology LaboratoriesTullahoma News•Jan 11, 2024•Epredia
•
Epredia Announces the U.S. Launch of SlideMate Laser | Provides State-of-the-Art Precision Slide Printing for Pathology LaboratoriesMedical Device News•Jan 11, 2024•Epredia
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Epredia
Explore our recently published companies
- Entrans - Prague based, 2003 founded, Funding Raised company
- Evolvez - New York based, 2019 founded, Unfunded company
- Kognico - New York based, 2003 founded, Unfunded company
- Happy Shark Media - New York based, 2019 founded, Unfunded company
- Spartan Institutional Research - New York based, 1996 founded, Unfunded company
- Ayoki Fabricon - Pune based, 1984 founded, Unfunded company
